The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: A rare disease with new clinical insights

European Journal of Haematology

Volumn 88, Issue 5, 2012, Pages 450-454

  Cañueto, Javier ^a   Labrador, Jorge ^b   Román, Concepción ^a   Santos Briz, Ángel ^b,c   Contreras, Teresa ^b   Gutiérrez, Norma Carmen ^b   García Sanz, Ramón ^b  

^a University Hospital of Salamancal   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

Author keywords

Monoclonal gammopathies; Scleromyxedema; T(14; 16); Transplant

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; DEXAMETHASONE; FERRIC HYDROXIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE; SYNDECAN 1; THROMBOCYTE CONCENTRATE;

ADULT; ALOPECIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ELECTROPHORESIS; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; HUMAN; MUCINOSIS; MUCOSA INFLAMMATION; PLASMA CELL; PRIORITY JOURNAL; RELAPSE; SCLEROMYXEDEMA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HUMANS; PYRAZINES; SCLEROMYXEDEMA;

EID: 84859623049     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01772.x     Document Type: Article

References (16)

1. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001;44:273-81.
2. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003;42:31-5.
3. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2006;107:463-6.
4. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, Kumar S, Litzow MR, Schroeter AL. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 2005;141:1277-82.
5. Ataergin S, Arpaci F, Demiriz M, Ozet A. Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. Am J Clin Dermatol 2008;9:271-3.
6. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-5.
7. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978;199:545-7.
8. Rongioletti F, Amantea A, Balus L, Rebora A. Cutaneous focal mucinosis associated with reticular erythematous mucinosis and scleromyxedema. J Am Acad Dermatol 1991;24:656-7.
9. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520-30.
10. Lopez-Corral L, Gutierrez NC, Vidriales MB, Mateos MV, Rasillo A, Garcia-Sanz R, Paiva B, San Miguel JF. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011;17:1692-700.
11. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87:10-20.
12. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 2001;137:1071-2.
13. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
14. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
15. Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011;35:e209-11.
16. Fett NM, Toporcer MB, Dalmau J, Shinohara MM, Vogl DT. Scleromyxedema and dermato-neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011;86:893-6.